See What's Inside
Read this FREE issue now
For healthcare professionals only
  • What's on the Horizon with Diabetes Research and Therapy
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter
Latest
Popular
Top Rated

Novo Nordisk Article Archives

August 2014

Weekly Dulaglutide Performs Well in Comparison to Daily Liraglutide

A comparison of the effects on A1c between users of once-weekly dulaglutide (made by Eli Lilly and Company) and once-daily liraglutide (sold as Victoza from Novo Nordisk) shows that both drugs have very similar effects.

comments 0 comments - Posted Aug 1, 2014

July 2014

Novo Nordisk Introduces New Insulin Device to U.S. Market

Novo Nordisk has introduced the Levemir® FlexTouch® prefilled insulin delivery device to the U.S. market. The device, filled with insulin detemir [rDNA origin], the first of its kind that does not use a pushbutton extension. In a conventional insulin delivery device, a pushbutton extends out from the device. If the called-for dose is large, an extension may cause problems for the user.

comments 0 comments - Posted Jul 26, 2014

Fewer Hypoglycemic Episodes With One Insulin in Head-to-Head Comparison

A recently completed study that compared two types of insulin for treating inadequately controlled type 2 patients showed that insulin degludec/insulin aspart produced fewer instances of hypoglycemia than biphasic insulin aspart 30.

comments 0 comments - Posted Jul 2, 2014

June 2014

NBA Hall of Famer Dominique Wilkins: Has A Slam Dunk Formula for Diabetes

NBA Hall of Famer Dominique Wilkins, affectionately known as “The Human Highlight Film” has a few coaching tips for people with diabetes.

comments 0 comments - Posted Jun 30, 2014

March 2014

Rev Run and Wife Justine Make Diabetes Prevention a Family Affair

Your family can be the most important tool in your arsenal when it comes to preventing the onset of type 2 diabetes or managing existing symptoms.

comments 0 comments - Posted Mar 14, 2014

FDA Backtracks Over GLP-1s' Effects on Pancreas

The U.S. Food and Drug Administration reports that its review of various animal and human studies does not show a link between GLP-1 drugs used to treat type 2 diabetes and pancreatic maladies, including acute pancreatitis and pancreatic cancer.

comments 0 comments - Posted Mar 4, 2014

February 2014

Weekly Type 2 Drug to Be Delivered Via Needle Patch

A recent agreement between Zosano Pharma, Inc. and Novo Nordisk could lead to the introduction of a once-weekly drug for type 2s that is administered via a micro-needle patch system.

comments 0 comments - Posted Feb 24, 2014

January 2014

Novo Announces U.S. Launch of NovoPen Echo® Insulin Injection Device

Plainsboro, N.J.--Novo Nordisk has announced the U.S. launch of its NovoPen Echo® insulin delivery device. It is the first and only pen device available in this country with half-unit dosing and a memory function that records the dose and time passed since the last injection.

comments 0 comments - Posted Jan 24, 2014

Study Strengthens Type 2-Inflammation Link

According to the results of a recent study, the onset of type 2 diabetes may be more closely related to inflammation than previous research has suggested.

comments 0 comments - Posted Jan 22, 2014

December 2013

Doctors Ask for Diabetes Patient Input Only 29% of the Time

Results from the global Diabetes Attitudes, Wishes and Needs 2 study (DAWN2TM) presented December 5 at a symposium during the World Diabetes Congress of the International Diabetes Federation in Melbourne, Australia, show that only 29 percent of people with diabetes report that their healthcare team asks for their input when making their treatment plans.

comments 0 comments - Posted Dec 11, 2013

August 2013

FDA Clears Novo's Kid-Friendly Insulin Pen

The U.S. Food and Drug Administration has granted 510(k) clearance for the NovoPen Echo®, the first insulin injection device on the market to combine half-unit dosing with a memory function to help patients manage their diabetes.

comments 0 comments - Posted Aug 22, 2013

March 2013

Novo Nordisk Still Accepting Community Star Entries

Share Your NovoLog® (insulin aspart [rDNA origin] injection) Community Star Story for the Chance to Win a Donation to the Charity of Your Choice!

comments 0 comments - Posted Mar 4, 2013

January 2013

Novo Nordisk and Two-Time Super Bowl Champion Kendall Simmons Kick-Off Search for Type 2 Diabetes Patients Who Give Back to Their Communities

Share Your NovoLog® (insulin aspart [rDNA origin] injection) Community Star Story for the Chance to Win a Donation to the Charity of Your Choice!

comments 0 comments - Posted Jan 22, 2013

He’s a Type 1 on TV and in Real Life

Forty-three year old stage and TV actor Stephen Wallem is a jack of all trades when it comes to entertainment. Best known for his one-man musical review, "Off the Wallem," he is also a playwright, composer, and director. Currently, he plays Thor, a gay nurse with type 1 diabetes, on the Showtime series "Nurse Jackie."

comments 1 comment - Posted Jan 12, 2013

December 2012

Brown, White and Beige: Not in Fashion But in Fat

To help stem the obesity epidemic, researchers are looking at how certain hormones act on fat cells. Scientists know that "white" fat cells store fat while "brown" fat cells not only store fat but also turn it into energy, a process that goes awry in obesity.

comments 0 comments - Posted Dec 23, 2012

Behind the Wheel, But Still in Control

Last May, 24-year-old Charlie Kimball was in Car #35, taking Turn 3 at the Indianapolis Motor Speedway during the Firestone Freedom 100. He was in radio contact with his pit crew, who informed him that he had a headwind coming out of the turn and onto the 5/8 mile "straight." Charlie kept an eye on the car next to him, moving closer and beginning to crowd it on the inside. Having raced professionally for six years, he knew that he had to make a move, and soon. He shifted into sixth gear and accelerated.

comments 1 comment - Posted Dec 4, 2012

November 2012

Lilly Says Its New Injectible Outperforms 3 Popular Diabetes Drugs

Good news for Eli Lilly & Co., as well as for type 2s who appreciate the addition of new drugs to treat their condition: Lilly says its once-weekly injectible drug, dulaglutide, has outperformed three other widely taken diabetes drugs in three just-concluded Phase III studies.

comments 0 comments - Posted Nov 5, 2012

August 2012

Paula Deen: Cooking Up a New Life With Diabetes

Paula Deen, a celebrity Southern chef known for her unrestrained love of butter and sugar, is no stranger to the media. She received a flurry of bad press recently when she revealed that she had been diagnosed with type 2 diabetes three years earlier. Shortly thereafter, she became a spokesperson for Novo Nordisk's Victoza. Following these developments, some critics said that she was a poor role model. 

comments 2 comments - Posted Aug 28, 2012

May 2012

Diabetes on the Rise in Saudi Arabia

Diabetes is increasingly taking hold in Saudi Arabia and other countries in the Middle East.  According to Dr. Ala Alwan, assistant director general for noncommunicable diseases and mental health at the World Health Organization (WHO), the problem is already vast and is increasing at an alarming rate.

comments 0 comments - Posted May 29, 2012

Insulin degludec

Novo Nordisk's new variety of long-lasting insulin, insulin degludec, reduces low blood sugars while improving overall control, according to a pair of studies published in the prestigious journal The Lancet on April 27.

comments 0 comments - Posted May 8, 2012

April 2012

FDA Says Levemir OK for Pregnant Women

The U.S. Food and Drug Administration says that Levemir is safe for use by pregnant women and does not increase the risk of harm to children in the womb.

comments 1 comment - Posted Apr 4, 2012

February 2012

Hypoglycemia Affects Productivity at Work

A survey of type 1 and type 2 diabetes patients in the United States, United Kingdom, France, and Germany indicates that more than one in every five have arrived late at work or not shown up at all because of a hypoglycemic episode the night before.

comments 16 comments - Posted Feb 21, 2012

FDA Gives Long-Awaited Nod to Amylin’s Bydureon

After several years of delays and setbacks, Amylin Pharmaceuticals has received FDA approval to begin US marketing of BydureonTM. The first once-a-week type 2 therapy to be offered in the US market, Bydureon is expected to be available by February. Amylin says that its wholesale price will be about $4,200 a year.

comments 2 comments - Posted Feb 3, 2012

January 2012

DiabetesSisters’ National Conference Set for May 18-20 in Raleigh, NC

RALEIGH, NC- DiabetesSisters is pleased to announce that registration for the 2012 Weekend for Women Conference opened on January 1, 2012, at 8 AM. The conference, a revolutionary weekend designed specifically for women with diabetes, will take place Friday, May 18, through Sunday, May 20, 2012, at the Marriott City Center in downtown Raleigh.

comments 0 comments - Posted Jan 24, 2012

December 2011

Novo Says Early Use of Victoza Aids Type 2 Control

News from Danish pharmaceutical manufacturer Novo Nordisk reinforces the growing trend toward using a two-drug combination in the early treatment of type 2 diabetes. (See "A Conversation About Janumet and Earlier Combination Therapy Type 2 Diabetes" for more discussion about the phenomenon.)

comments 2 comments - Posted Dec 15, 2011

October 2011

Novo Nordisk Files for FDA Approval of New Insulin

A brand new insulin will soon be on pharmacy shelves in the United States if Danish pharmaceutical company Novo Nordisk has its way. The company has filed for approval from the Food and Drug Administration to sell insulin degludec, an original formulation that lasts an extra-long time. Insulin degludec is injected only once a day. Once under the skin, the dose of insulin is absorbed slowly and consistently, allowing for better nighttime control, according to Novo. Most importantly, test subjects had a low rate of hypoglycemia on the drug.

comments 2 comments - Posted Oct 15, 2011

Novo Says Early Use of Victoza Aids Type 2 Control

News from Danish pharmaceutical manufacturer Novo Nordisk reinforces the growing trend toward using a two-drug combination in the early treatment of type 2 diabetes. (See "A Conversation About Janumet and Earlier Combination Therapy for Type 2 Diabetes" for more discussion about this phenomenon.) In a study it released in Lisbon, Portugal, at the recent meeting of the European Association for the Study of Diabetes, Novo said that combining its recently released drug Victoza® (liraglutide) with another drug early in therapy helps recently diagnosed type 2s achieve greater blood glucose control than they can with a single drug.

comments 0 comments - Posted Oct 2, 2011

September 2011

Do What You Love, and It Will Never Be Work

Being a rookie driver on the fast-paced IndyCar racing circuit is pressure enough for any 26-year-old. But for Charlie Kimball, one of four wheel men on businessman Chip Ganassi's IndyCar race team, there's the added need to manage type 1 diabetes while roaring around the track at speeds that often exceed 200 miles per hour.

comments 0 comments - Posted Sep 25, 2011

The State of Insulin Injection

What's Being Researched Now

comments 4 comments - Posted Sep 11, 2011

July 2011

Type 2 Drug Victoza Helps Type 1s, Too

Victoza, a drug aimed at type 2 diabetes, may turn out to be a boon for type 1 diabetes patients as well. A small clinical study shows that patients with well-controlled type 1 who took Victoza daily for just one week experienced a 15 percent drop in their blood sugar levels. Patients who took the drug over a full 24-week test period needed less and less insulin, decreasing their average mealtime dose by seven units and their all-day insulin requirement by eight.

comments 2 comments - Posted Jul 11, 2011

May 2011

Sanofi Says Late-Stage Trial of Type 2 Drug a Success

French drug maker Sanofi-aventis says that results from a Phase III trial of its experimental type 2 diabetes drug lixisenatide show that the drug successfully lowered patients' blood glucose levels and body weight, but did not increase the risk of hypoglycemia.

comments 0 comments - Posted May 23, 2011

Albertson’s Supermarket Chain Joins Diabetes Alliance

Albertson's LLC, a nationwide supermarket chain with more than 200 stores, has announced that it will participate in the Diabetes Control Program (DCP) of the Diabetes Prevention and Control Alliance. The DCP works through trained pharmacists to provide education and support to people with diabetes.

comments 0 comments - Posted May 7, 2011

March 2011

Novo Nordisk Joins Nationwide Diabetes/Pre-Diabetes Treatment Alliance

Novo Nordisk, the world's largest insulin manufacturer, has joined the Diabetes Prevention and Control Alliance (DPCA), a group whose goals are to reduce people's risk of developing diabetes and to work with people who already have it.

comments 1 comment - Posted Mar 4, 2011

February 2011

Insulin Needle Wins Design Prize, But You Can't Buy It in the States

The Chicago Athenaeum: Museum of Architecture has announced its 60th annual Good Design Awards, which honor "quality design of the highest form, function, and aesthetic." Guess which paragon of contemporary design won an award this year? An insulin needle. Called the NovoTwist and made by Novo Nordisk for use with insulin pens, this marvel of design has a bayonet fitting that allows "just twist" attachment and detachment to compatible pens, and an audible and tactile "click" that confirms attachment of the needle.

comments 4 comments - Posted Feb 1, 2011

January 2011

DiabetesSisters' National Conference Addresses Unique Challenges of Women with Diabetes

RALEIGH, NC- DiabetesSisters is pleased to announce that registration for the 2011 Weekend for Women Conference in Raleigh, NC will open on January 1, 2011 at 8am.  The Conference, a revolutionary national weekend conference designed specifically for women with diabetes, will take place April 29 - May 1, 2011 at the Marriott City Center in downtown Raleigh.    

comments 0 comments - Posted Jan 5, 2011

December 2010

Charlie Kimball to Pilot New IndyCar Entry

Novo Nordisk, a world leader in diabetes care, has partnered with Chip Ganassi Racing, LLC to create the Novo Nordisk Chip Ganassi Racing team for the 2011 IZOD IndyCar season. The team will sponsor a new entry in the series driven by American racecar driver Charlie Kimball. This partnership makes Kimball one of the first drivers from the 2010 Firestone Indy Lights series to move up the official "Road to Indy" with a full season sponsorship.

comments 0 comments - Posted Dec 16, 2010

Twenty Community-Based Organizations Across the United States Receive Awards to Encourage Seniors to Get Screened for Diabetes

Leaders of the Medicare Diabetes Screening Project (MDSP) announced that twenty community-based organizations from 17 states were given awards of $2,500 each to be used to encourage seniors ages 65 and older who are covered under Medicare to get screened for diabetes.

comments 0 comments - Posted Dec 10, 2010

October 2010

Calibra Gains FDA Clearance to Market Finesse

Calibra Medical has announced that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its FinesseTM insulin patch-pen for up to three-day use with Novo Nordisk's Novolog® rapid-acting insulin. This much-anticipated step closer to market release follows the announcement in January that Calibra received FDA clearance for the device for use with Eli Lilly's Humalog® rapid-acting insulin.

comments 1 comment - Posted Oct 18, 2010

August 2010

Novo Nordisk Creates "App" to Help Doctors Dose Insulin

Novo Nordisk announced today the availability of NovoDoseTM - the first-ever mobile insulin dosing guide for physicians to look up dosing guidelines and blood glucose goals for their patients with diabetes, a disease that affects nearly 24 million Americans. The guide is available as an application on iTunes and is specific to Novo Nordisk's modern insulin analog portfolio: Levemir® (insulin detemir [rDNA origin] injection), NovoLog® (insulin aspart [rDNA origin] injection), and NovoLog® Mix 70/30 (70% insulin aspart protamine suspension and 30% insulin aspart injection, [rDNA origin]).

comments 0 comments - Posted Aug 24, 2010

Victoza® Achieved Improved Blood Sugar Control in African-Americans With Type 2 Diabetes

Novo Nordisk presented results demonstrating that once-daily Victoza® (liraglutide [rDNA] injection) achieved significantly greater improvements in blood sugar control compared to placebo among African-American patients with type 2 diabetes. The meta-analysis of phase 3 data from the Liraglutide Effect and Action in Diabetes (LEAD) trials were presented at the 2010 National Medical Association Annual Convention & Scientific Assembly.

comments 0 comments - Posted Aug 5, 2010

July 2010

Pump and Sensor Combo Beats MDI Decisively in Medtronic’s STAR 3 Study

A massive study involving 485 people with type 1 diabetes at 30 locations across North America shows that the combination of an insulin pump and a continuous glucose monitor helps patients achieve significantly lower A1c levels than multiple daily insulin injections.

comments 0 comments - Posted Jul 13, 2010

More from ACCORD

In people with longstanding type 2 diabetes who are at high risk for heart attack and stroke, lowering blood sugar to near-normal levels did not delay the combined risk of diabetic damage to kidneys, eyes, or nerves, but did delay several other signs of diabetic damage, a study has found. The intensive glucose treatment was compared with standard glucose control.

comments 0 comments - Posted Jul 2, 2010

June 2010

Academia, Biotech and the Pharmaceutical Industry Have Joined Forces to Fight Diabetes

IMIDIA ("Innovative Medicines Initiative for Diabetes"), a public private consortium funded by the Innovative Medicines Initiative (IMI), announced today the launch of a project focusing on pancreatic islet cell function and survival. Academia, biotech and pharma industry have joined forces to develop biomarkers and tools to pave the way for improved disease management and ultimately provide a cure for diabetes.

comments 0 comments - Posted Jun 18, 2010

April 2010

Novo Nordisk Introduces New Industry Resource for Information on Diabetes and Chronic Disease

Novo Nordisk, a global healthcare company and leader in diabetes care, announced the launch of the Novo Nordisk BlueSheet, a resource for information on diabetes and chronic disease, highlighting key issues in diabetes prevention, detection, treatment and care.

comments 0 comments - Posted Apr 4, 2010

March 2010

FDA Hedges Approval of Long-Acting Byetta, Asks Amylin for More Information

The U.S. Food and Drug Administration has withheld approval of Bydureon, the once-weekly version of the popular type 2 diabetes drug Byetta.  The agency has asked its manufacturer, Amylin, for more information regarding Bydureon's manufacture, labeling, and risk management plan. It did not, however, request further information on tests of the drug itself-an indication that the agency probably intends to grant marketing permission once it has dotted all the i's and crossed all the t's involved in the approval process.

comments 0 comments - Posted Mar 29, 2010

Starting Treatment Early Doubles Chance of Success for People with Diabetes

The sooner people with diabetes start taking metformin, the longer the drug remains effective, according to a Kaiser Permanente study published in the March issue of Diabetes Care, a journal of the American Diabetes Association.

comments 2 comments - Posted Mar 12, 2010

Amylin Hopes to Begin U.S. Sales of Long-Acting Byetta Early This Year

Amylin Pharmaceuticals has announced that it expects to begin selling a once-weekly version of its diabetes drug, Byetta, by the end of the year. The company reports that the FDA is nearing final inspections of its manufacturing plant and could give the go-ahead for U.S. sales in early March.

comments 2 comments - Posted Mar 4, 2010

February 2010

FDA Gives Novo the Go-Ahead to Market Victoza® in the U.S.

Danish pharmaceutical company Novo Nordisk has received Food and Drug Administration permission to begin marketing its type 2 drug Victoza® in the United States.
Victoza, the brand name for liraglutide, is a GLP-1* analog that is taken one a day by injection to help control blood sugar-and in some cases, help with weight loss-in patients with type 2 diabetes.

comments 5 comments - Posted Feb 27, 2010

Diabetes and Pre-Diabetes Cost the U.S. $218 Billion in 2007: En Route to $336 Billion by 2034

A study commissioned by healthcare company Novo Nordisk has reported that the cost of diabetes and pre-diabetes to the U.S. economy in 2007 was $218 billion. The study, conducted by The Lewin Group, projected that by 2034, the two conditions will cost the economy $336 billion per year.

comments 1 comment - Posted Feb 3, 2010

Novo, Upping the Ante in the Race for an Oral GLP-1 Drug, Tests a Pill Version of Victoza

Denmark-based Novo Nordisk has begun a Phase 1 trial of a pill form of a GLP-1 drug very similar to its Victoza product. The trial will involve  155 British patients with type 2 diabetes. The test on human subjects, although very early-stage,  puts the company in the lead to develop an oral form of a GLP-1 drug.

comments 0 comments - Posted Feb 1, 2010

January 2010

Novo Nordisk's Victoza Receives FDA Approval for the Treatment of Type 2 Diabetes

Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) approved the new drug application for Victoza (liraglutide injection), the first once-daily human glucagon-like peptide-1 (GLP-1) analog for the treatment of type 2 diabetes. Victoza is indicated as an adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus.

comments 4 comments - Posted Jan 28, 2010

December 2009

Novo Enters Phase 1 Test of an Insulin Pill

Denmark-based Novo Nordisk A/S has begun phase 1 testing of an insulin pill that, if successful, could replace injections as the primary means of blood sugar control for millions of people with type 1 and type 2 diabetes. The company has enrolled 80 volunteer German test subjects in the study and expects to have preliminary results by the first half of 2011. The test group consists of both people with diabetes and people without it.

comments 12 comments - Posted Dec 24, 2009

November 2009

Diabetes Population to Double and Diabetes Costs to Nearly Triple in 25 Years, New Study Shows

PRINCETON, NJ (November 27, 2009) - The diabetes population in the United States will almost double over the next 25 years and annual medical spending on the disease is projected to hit $336 billion, up from $113 billion today, according to a study published in the December issue of Diabetes Care.  The National Changing Diabetes® Program (NCDP), a program of Novo Nordisk, commissioned the analysis by a team from the University of Chicago.

comments 5 comments - Posted Nov 27, 2009

Primary Care Doctors, Endocrinologists Feel Ill-Equipped to Provide Ideal, Multi-Disciplinary Team Care

PRINCETON, N.J., Nov. 19 /PRNewswire/ -- Nearly one-third of doctors surveyed said they did not have enough time and did not receive sufficient reimbursement to provide comprehensive care to their patients with diabetes, according to the results of a study of endocrinologists and primary care doctors published in American Health & Drug Benefits.

comments 4 comments - Posted Nov 20, 2009

October 2009

Afresa: A New Insulin (By the Way, It's Inhaled)

The enthusiasm for inhaled insulin has waned, to say the least, since Exubera was pulled off the market by Pfizer. Following the Exubera debacle, the development of two other inhaled insulins (AIR by Eli Lilly and Alkermes, and AERx by Novo Nordisk) was halted as well.

comments 14 comments - Posted Oct 5, 2009

September 2009

American Diabetes Association Research Foundation and Novo Nordisk Award Grant to Study Intestinal Hormones

ALEXANDRIA, VA, Sep 01, 2009 (MARKETWIRE via COMTEX) - The American Diabetes Association Research Foundation has selected two scientists, University of Virginia Health System researcher Zhenqi Liu, MD, and Stanford University School of Medicine researcher Gerald Reaven, MD, to receive the American Diabetes Association-Novo Nordisk Clinical/Translational Research Award.

comments 0 comments - Posted Sep 12, 2009

August 2009

Olympia Dukakis and Her Husband Tackle Type 2 Together

Three days after a routine physical last November, 84-year-old Louis Zorich was called by his doctor and told that he had type 2 diabetes. The first words out of the seasoned actor's mouth were "There's been a mistake." Louis, who's been married to Academy Award-winning actress Olympia Dukakis for 47 years, proceeded to explain (incorrectly) to his doctor, "Men don't get diabetes. My three brothers don't have it, but my mother had it....It may be genetic, but only the female side of my family can have diabetes."

comments 2 comments - Posted Aug 21, 2009

An Insulin Primer

Until the twentieth century, type 1 diabetes was a fatal disease. Once we came to understand how insulin works in the body, however, everything changed. The discovery of the role of insulin was a group effort by people who didn't know each other, but built on each others' work. In 1869, a German medical student named Paul Langerhans figured out the regulatory role of insulin in the mammal body. In honor of his efforts, his name was given to the islets of Langerhans, where insulin is synthesized within the beta cells of the pancreas. Other Europeans and North Americans made important advancements right up until January 23, 1922, when a 14-year-old boy who was dying of diabetes at Toronto General Hospital was given the first successful injection of cow insulin.

comments 2 comments - Posted Aug 10, 2009

Behind the Wheel, But Still in Control

Last May, 24-year-old Charlie Kimball was in Car #35, taking Turn 3 at the Indianapolis Motor Speedway during the Firestone Freedom 100. He was in radio contact with his pit crew, who informed him that he had a headwind coming out of the turn and onto the 5/8 mile "straight." Charlie kept an eye on the car next to him, moving closer and beginning to crowd it on the inside. Having raced professionally for six years, he knew that he had to make a move, and soon.  He shifted into sixth gear and accelerated.

comments 2 comments - Posted Aug 8, 2009

Liraglutide Tested on African Americans with Type 2 Diabetes

Most clinical studies of new drugs are conducted primarily on white men, whether or not they are most affected by the disease the drug is intended to treat.  African Americans, for example, are 1.6 times more likely to have diabetes than non-Hispanic whites.  Why should we assume that what works for white males will also be effective for African Americans, Hispanics, Asians, or, for that matter, women?

comments 0 comments - Posted Aug 6, 2009

July 2009

Why Does Insulin Cost More Than Ever? It's All In The Way It's Made

Banting Gives It Away - Insulin was discovered in 1921 by Fred Banting and Charles Best. In a generous gesture that unfortunately didn't start a trend, they sold the patent for a dollar so that cheap insulin would quickly become available. It worked like a charm: within two years, Eli Lilly had sold 60 million units of its purified extract of pig and cow pancreas.

comments 27 comments - Posted Jul 27, 2009

June 2009

FDA Issues Public Health Advisory Regarding Levemir Insulin

The U.S. Food and Drug Administration has learned that some stolen vials of the long-acting insulin Levemir made by Novo Nordisk Inc. have reappeared and are being sold in the U.S. market. Three lots or a total of 129,000 vials of this product were stolen in all. These stolen insulin vials may not have been stored and handled properly and may be dangerous for patients to use.

comments 1 comment - Posted Jun 22, 2009

Insulin Analog Levemir Lowers BG Levels in 60 Percent of Type 2 Patients

Novo Nordisk has announced that results from a study show that almost 60 percent of type 2 patients taking once-daily doses of its Levemir insulin analog were able to reach the average blood sugar level recommended by the American Diabetes Association. 

comments 3 comments - Posted Jun 2, 2009

May 2009

Type 2 Drugs: EU Approves “Victoza,” FDA Extends Review of “Onglyza”

The European Union's drug regulation agency has recommended that the EU approve the marketing of "Victoza" (liraglutide), a type 2 drug developed by Novo Nordisk.

comments 2 comments - Posted May 6, 2009

April 2009

Apidra SoloSTAR Pen Now Available in the United States

Insulin pens have been very popular in Europe for quite some time and interest is building steadily in the United States. Many people prefer an insulin pen over the standard syringe and vial because the pens are more convenient and more accurate.  Pre-filled disposable insulin pens are the easiest of all, because you don't never have to install a new cartridge when the pen is empty-you just toss it out.

comments 4 comments - Posted Apr 28, 2009

March 2009

FDA Poised to Review Two New Drugs for Type 2 Diabetes

The FDA has announced that starting in early April, its Endocrinologic and Metabolic Drugs Advisory Committee will begin looking into two new drugs for type 2 diabetes: saxagliptin tablets from Bristol-Meyers Squibb and liraglutide, an injection drug from Novo Nordisk.

comments 1 comment - Posted Mar 24, 2009

Insulin Pen Instead of Syringe Saves Hospital Bills For Type 2s

In a study funded by Novo Nordisk, researchers at Ohio State University have found that type 2s who move from oral meds to insulin would be wise to start with an insulin pen rather than a syringe.

comments 16 comments - Posted Mar 21, 2009

Novo Nordisk’s Improved FlexPen® Now Available in the U.S.

Novo Nordisk has redesigned the FlexPen®, the number one selling pre-filled insulin pen in the world, to not only require less force when pushing the button to inject insulin, but also to clearly identify each type of insulin with prominent color branding. The FlexPen® is available with three Novo Nordisk insulin products: Levemir® (insulin detemir [rDNA origin] injection); NovoLog® (insulin aspart [rDNA origin] injection); and NovoLog® Mix 70/30 (70% insulin aspart protamine suspension and 30% insulin aspart injection, [rDNA origin]).

comments 6 comments - Posted Mar 18, 2009

February 2009

Liraglutide Best at Reducing A1c’s When Used in a Two-Drug Combo

Data from a phase 3 study of the Novo Nordisk drug liraglutide shows that when it is used in combination with glimepiride, it is more effective at reducing A1c's than glimepiride by itself or glimepiride in combination with the drug rosiglitazone. 

comments 0 comments - Posted Feb 19, 2009

December 2008

Readers Challenge Insulin Manufacturers: Help Us Avoid Near-Fatal Mistakes!
Readers Challenge Insulin Manufacturers: Help Us Avoid Near-Fatal Mistakes!

Sandy was giving her son his evening dose of NPH insulin - something she had done many times. But as she finished pushing in the plunger, she said to herself, "That shot took too long." She immediately realized that she had given Joey the wrong dose. In other words, by mistake, she had given him a potentially lethal dose of insulin.

comments 61 comments - Posted Dec 25, 2008

November 2008

Diabetes Costs U.S. $218 Billion in 2007

According to a study sponsored by Danish pharmaceutical company Novo Nordisk, it cost $218 billion to treat type 1 and 2 diabetes in the United States in 2007. Of that amount, the federal government spent approximately $85 billion.

comments 1 comment - Posted Nov 24, 2008

Young People With Diabetes Urgently Need Social and Psychological Support

According to a global survey studying children with diabetes, current healthcare systems are failing to give adequate social and psychological support to young people with diabetes. This lack of support often leads to poor control of their disease, resulting in long-term health complications. 

comments 0 comments - Posted Nov 24, 2008

October 2008

New Data From Phase 3 Trial Says Liraglutide Is More Effective Than Exenatide For Type 2s

Novo Nordisk recently announced results from its LEAD 6 study showing that once daily liraglutide was significantly more effective at improving blood glucose control (as measured by A1c) than exenatide, a GLP-1 mimetic administered twice daily.

comments 4 comments - Posted Oct 27, 2008

New Drug Shows Exenatide-Like Promise in Type 2 Treatment

An experimental exenatide (Byetta)-like drug called liraglutide has shown the ability to enhance insulin and glucagon production and suppress appetite in type 2 patients, according to a report in the British medical journal The Lancet.

comments 0 comments - Posted Oct 13, 2008

June 2008

Diabetes Getting You Down? Women Can Improve Their Inner Care by Focusing on Their Outer Beauty for a Day
Diabetes Getting You Down? Women Can Improve Their Inner Care by Focusing on Their Outer Beauty for a Day

How would you describe a minor hiccup in your daily care that  just happens out of the blue, especially when just moments before, you felt fine and everything seemed perfect? That’s a ‘diabetes bad hair day’ according to Divabetic, a national nonprofit diabetes outreach organization, currently on tour with its free national diabetes outreach program, ‘Novo Nordisk Presents: Divabetic – Makeover Your Diabetes.’

comments 1 comment - Posted Jun 19, 2008

Novo Nordisk Seeks U.S. and European Approval for Type 2 Drug Liraglutide
Novo Nordisk Seeks U.S. and European Approval for Type 2 Drug Liraglutide

Drug manufacturer Novo Nordisk has applied to the U.S. Federal Drug Administration and the European Medicines Agency for approval of liraglutide, a human GLP-1 analog* that is taken once daily for the treatment of type 2 diabetes.

comments 0 comments - Posted Jun 19, 2008

Sign Up to Join Diabetes Health's Visionary Plan

Dear friends of Diabetes Health,

We value your hard-earned diabetes wisdom and we want you to share it with the world! Please join us as a professional or lay diabetes advisor in one of our Diabetes Health website content Rooms.

comments 3 comments - Posted Jun 6, 2008

Robert Oringer: The Entrepreneur Who Pioneered Private-Label Diabetes Products
Robert Oringer: The Entrepreneur Who Pioneered Private-Label Diabetes Products

In the 17 years I have known Robert Oringer, I can honestly say that he has a soaring entrepreneurial spirit and a fierce independence – he is a man who is hard to harness. His mind is always ticking, excited by the next innovative idea.

comments 2 comments - Posted Jun 2, 2008

May 2008

Dancing With the Stars' Drew Lachey will Judge Dancin' to Change Diabetes
Dancing With the Stars' Drew Lachey will Judge Dancin' to Change Diabetes

ABC’s Dancing with the Stars champion Drew Lachey has teamed up with Novo Nordisk to launch the first national online video contest to increase diabetes awareness, Dancin’ to Change Diabetes.

comments 0 comments - Posted May 15, 2008

April 2008

Pfizer Halts Sales of Exubera In Wake of Lung Cancer Fears
Pfizer Halts Sales of Exubera In Wake of Lung Cancer Fears

In wake of news that its inhaled insulin product Exubera has been linked to lung cancer, Pfizer Inc. has announced that it will cease manufacturing the drug and update labels on the remaining product to carry a cancer warning.

comments 6 comments - Posted Apr 17, 2008

In New York, Pump Wear Inc. Invites 14 Families to a Free Weekend Camp

On April 25-27, 14 families of children with diabetes will enjoy a weekend at the Double H Ranch in Lake Luzerne, N.Y., thanks to Pump Wear Inc., which manufactures insulin pump-related accessories.

comments 2 comments - Posted Apr 9, 2008

December 2007

Interesting Insulin Facts
Interesting Insulin Facts

The name insulin comes from the Latin insula, for islands. It refers to the pancreatic islets of Langerhans that contain the beta cells.

comments 3 comments - Posted Dec 20, 2007

November 2007

Novo Touts Levemir as a 24-Hour Insulin

Novo Nordisk's Levemir, which came out about five years after sanofi-aventis's Lantus, constitutes about twenty percent of the long-acting basal insulin sold worldwide. Lantus, the only other long-acting insulin analogue, makes up the other eighty percent.

comments 3 comments - Posted Nov 26, 2007

Insulin: How To Restore A Tarnished Miracle
Insulin: How To Restore A Tarnished Miracle

It was hailed as a "miracle cure," restoring life to the "erstwhile dead" and delivering not just health, but "salvation." Discovered in 1922, insulin did not live up to the initial euphoria - it didn't cure anything - but the life-saving elixir still stands as one of the greatest breakthroughs in medical history.

comments 7 comments - Posted Nov 20, 2007

The Crisis in Diabetes Education: Essential Care That's Riddled with Problems, and What We Can Do to Fix It
The Crisis in Diabetes Education: Essential Care That's Riddled with Problems, and What We Can Do to Fix It

Diabetes educators are no less than a lifeline for patients, providing vital insights into the self-care behaviors that keep diabetes in check: managing blood sugar, dosing medications and insulin, exercising, and understanding all the numbers involved.

comments 30 comments - Posted Nov 15, 2007

July 2007

Get Your Face on Novo Nordisk's "Face of Change"

"Meet the Face of Change," Novo Nordisk's exhibit of photographs and stories of people with type 2 diabetes, is getting underway. The pictures will be taken by Rick Smolan, famed photojournalist who produced the "Day in the Life" coffee table books.

comments 0 comments - Posted Jul 21, 2007

The Federal Government Hugely Out-of-Pocket for Diabetes Care
The Federal Government Hugely Out-of-Pocket for Diabetes Care

In 2005, the national government spent more on diabetes than on the entire budget for the Department of Education. One out of every eight dollars spent by the federal government on healthcare (twelve percent of all healthcare expenditures) went to diabetes.

comments 0 comments - Posted Jul 12, 2007

May 2007

Why Does Insulin Cost More Than Ever? It's All In The Way It's Made
Why Does Insulin Cost More Than Ever? It's All In The Way It's Made

Banting Gives It Away - Insulin was discovered in 1921 by Fred Banting and Charles Best. In a generous gesture that unfortunately didn’t start a trend, they sold the patent for a dollar so that cheap insulin would quickly become available. It worked like a charm: within two years, Eli Lilly had sold 60 million units of its purified extract of pig and cow pancreas.

comments 24 comments - Posted May 23, 2007

Divabetic Diabetes Program Adds a Tunnel of Love to Its Educational Offerings
Divabetic Diabetes Program Adds a Tunnel of Love to Its Educational Offerings

With its focus on the feminine and its message of community, Novo Nordisk’s Divabetic program is currently making its way across the nation. At Divabetic events, women are invited to explore a “Makeover Maze” of personalized diabetes education that’s light-years from the standard sterile clinical setting.

comments 0 comments - Posted May 9, 2007

ACP Unveils Internist Tools for Clinical Practice: Patient Workbook, Physician Guide, and Web Site Engage Physicians and Patients
ACP Unveils Internist Tools for Clinical Practice: Patient Workbook, Physician Guide, and Web Site Engage Physicians and Patients

PHILADELPHIA, April 19, 2007 - Eat right. Exercise. Monitor blood sugar. Take medication regularly. This is the advice physicians give the more than 20 million Americans affected with diabetes. Yet implementation of these recommendations is often far from ideal, putting patients at greater risk for damage to the heart, kidneys, eyes, and feet.

comments 0 comments - Posted May 3, 2007

April 2007

Dawn of an Interactive Diabetes Website
Dawn of an Interactive Diabetes Website

In 2001, the Diabetes Attitudes, Wishes, and Needs Study (DAWN) was undertaken to gather psychosocial data about why more than half of people with diabetes dont manage their diabetes all that well.

comments 0 comments - Posted Apr 26, 2007

NovoLog Approved for Pregnant Type 1's

On January 30, 2007, the FDA upgraded NovoLog (a fast-acting insulin analog from Novo Nordisk) from Category C to Category B, thereby indicating that NovoLog is safe and effective for pregnant women with type 1 and their unborn children.

comments 0 comments - Posted Apr 16, 2007

March 2007

World Decision-Makers Confront Diabetes Pandemic at Novo Nordisk Forum: Former President Bill Clinton, keynote speaker at the Forum

New York, NY - March 13, 2007 - Former President Bill Clinton joined global diabetes leaders today in New York City to discuss ways to break the curve of the diabetes pandemic at a forum hosted by Novo Nordisk and supported by the International Diabetes Federation (IDF).

comments 0 comments - Posted Mar 13, 2007

New Joslin Study Reveals How a Specific Fat Type Can Protect Against Weight Gain and Diabetes

BOSTON - March 1, 2007 - A new study from Joslin Diabetes Center may shed light on why some people can eat excessive amounts of food and not gain weight or develop type 2 diabetes, while others are more likely to develop obesity and this most common form of diabetes on any diet.

comments 0 comments - Posted Mar 7, 2007

February 2007

Former President Bill Clinton speaks at Novo Nordisk Forum on Urgent Need of Worldwide Change in Diabetes Care

PRINCETON, N.J. - January 25, 2007 - Former President Bill Clinton will be the keynote speaker at the Global Changing Diabetes Leadership Forum, taking place on March 13, 2007 in New York City hosted by Novo Nordisk and supported by the International Diabetes Federation.

comments 5 comments - Posted Feb 28, 2007

Fighting Diabetes at the Hottest Place on Earth
Fighting Diabetes at the Hottest Place on Earth

Death Valley is hardly a common place to be raising awareness of diabetes. This past fall, however, several hundred people with diabetes, healthcare professionals, and other bicyclists passionate about improving diabetes care rode 105 miles at upwards of 90 degrees to raise money for diabetes research in the Juvenile Diabetes Research Foundation (JDRF) “Ride to Cure Diabetes 2006.”

comments 0 comments - Posted Feb 1, 2007

January 2007

Divabetic is Bringing Sexy Back!
Divabetic is Bringing Sexy Back!

Hundreds of women affected by diabetes across the country are feeling great about themselves and learning to stay that way, thanks to an innovative diabetes outreach campaign presented by a world leader in diabetes care, Novo Nordisk.┬áCalled “Novo Nordisk Presents Divabetic—Makeover Your Diabetes,” the program combines personalized diabetes education with free salon and spa services in a crash course designed to help every woman’s “inner diva” take charge of her own and her family’s health.

comments 0 comments - Posted Jan 25, 2007

December 2006

Program Aimed to Bring Out Your Diabetes ‘Diva’
Program Aimed to Bring Out Your Diabetes ‘Diva’

Started as a t-shirt fundraiser, the Divabetic phenomenon is beginning to take on a life of its own. Max Szadek, personal assistant to the late Luther Vandross, once decided to begin selling t-shirts with the word “Divabetic” on them to empower and educate women living with, at risk of, or affected by diabetes.

comments 0 comments - Posted Dec 1, 2006

July 2006

Long-Acting Levemir Now Available

Novo Nordisk announced that Levemir is now commercially available in the United States.

comments 0 comments - Posted Jul 1, 2006

June 2006

The Ever-Changing Insulin Landscape
The Ever-Changing Insulin Landscape

In 1998, Eli Lilly & Co.’s rapid-acting insulin analogue lispro (Humalog) appeared on the U.S. market, followed in 2000 by Novo Nordisk’s rapid-acting counterpart aspart (NovoLog). Joined now by sanofi-aventis’ glulisine (Apidra), these rapid-acting insulins offer both convenience and improved blood glucose control to people who require bolus insulin.

comments 1 comment - Posted Jun 1, 2006

May 2006

New Long-Acting Insulin Now Available

My life depends entirely on getting little squirts of insulin into my bloodstream on a regular basis. Too little, and high blood glucose hijacks my moods—tired and cranky are the watchwords here. Too much insulin makes my BGs plummet—and shakiness and confusion take over until I eat something containing sugar.

comments 3 comments - Posted May 1, 2006

April 2006

Alan Moses, MD, is the medical director for Novo Nordisk Pharmaceuticals
Alan Moses, MD, is the medical director for Novo Nordisk Pharmaceuticals

With the new basal-bolus insulin landscape, what is the most important thing that endocrinologists and primary care physicians need to know so that their insulin-using patients can follow the best possible regimen?

comments 0 comments - Posted Apr 1, 2006

Do Your Insulin-Using Patients Know About Insulin Pens?
Do Your Insulin-Using Patients Know About Insulin Pens?

If you are an endocrinologist or primary care physician who works with diabetics, you have undoubtedly heard of the insulin pen. You probably know of their popularity in Europe or have heard testimonials from pen users about their ease of use.

comments 0 comments - Posted Apr 1, 2006

Patients Prefer Pens With Auditory and Sensory Confirmation
Patients Prefer Pens With Auditory and Sensory Confirmation

Because people with diabetes sometimes suffer from visual impairment as well as reduced manual dexterity, Japanese researchers assessed the reliability of dose selection and setting of five insulin devices by patients using auditory and sensory confirmation.

comments 0 comments - Posted Apr 1, 2006

Levemir, Apidra and Lantus—Oh My! How Do the New Insulin Analogues Affect the Care of Your Patients?

In 1998, Eli Lilly & Co.’s rapid-acting insulin analogue lispro (Humalog) appeared on the U.S. market, followed in 2000 by Novo Nordisk’s rapid-acting counterpart aspart (NovoLog). Joined now by sanofi-aventis’ glulisine (Apidra), these rapid-acting insulins offer both convenience and improved blood glucose control to your patients who require bolus insulin.

comments 0 comments - Posted Apr 1, 2006

Hala Khalaf Captures the Global Essence of Being Young With Diabetes
Hala Khalaf Captures the Global Essence of Being Young With Diabetes

Hala Khalaf is the author of “Young Voices: Life With Diabetes” (John Wiley & Sons, 2005). Her book is an intimate portrayal of how culture influences the daily lives of 13 young people with diabetes from around the world.

comments 0 comments - Posted Apr 1, 2006

February 2006

Novo Offers New Emergency Glucagon Injection
Novo Offers New Emergency Glucagon Injection

Christine Olinghouse, RD, RN, CDE, BC-ADM, says, “If your patients take insulin, a glucagon emergency kit is the best treatment system you can have for severe hypoglycemia.”

comments 0 comments - Posted Feb 1, 2006

Can Insulin Cause Cancer?

Richard K. Bernstein, MD, says that a potentially serious problem with eliminating Ultralente is the “long-term forecast of potential adverse effects” in people taking Lantus, as outlined by Ernst Chantelau, MD.

comments 5 comments - Posted Feb 1, 2006

Is Regular the Next to Go?
Is Regular the Next to Go?

Richard K. Bernstein fears that Regular insulin will be the next to vanish from the American market.

comments 0 comments - Posted Feb 1, 2006

And Then There Were Some

Since his type 1 diagnosis 20 years ago, Doug Frazer of Forest Knolls, California, had been using Lente as his basal insulin. His regimen of Humalog at mealtimes coupled with Lente at bedtime provided him with what he considered great control.

comments 0 comments - Posted Feb 1, 2006

January 2006

Scott Verplank
Scott Verplank

For Scott Verplank, staying on top of his diabetes with frequent blood glucose testing means staying on top of his game for the Professional Golf Association (PGA) Tour.

comments 9 comments - Posted Jan 1, 2006

December 2005

Letters to the Editor

Lilly Leaves Us With Fewer and Fewer Options

comments 0 comments - Posted Dec 1, 2005

September 2005

Hurricane Katrina
Hurricane Katrina

Hurricane Katrina is being called the worst natural disaster to hit the United States since the San Francisco Earthquake of 1906. Thousands of people were left stranded without adequate food, shelter, water, and medical supplies. Many of these people were diabetics who are now forced to struggle with unspeakable conditions and a lack of medical supplies necessary for the control of their diabetes.

comments 0 comments - Posted Sep 8, 2005

Levemir’s Approval Means One More Long-Acting Insulin Option for Diabetics
Levemir’s Approval Means One More Long-Acting Insulin Option for Diabetics

On June 17, 2005, Novo Nordisk received word from the U.S. Food and Drug Administration (FDA) that their long-acting insulin analog, Levemir (insulin detemir), had received approval. Levemir will join Lantus (insulin glargine) as a basal insulin option for people with diabetes who take insulin.

comments 0 comments - Posted Sep 1, 2005

August 2005

New Book Explores the Voices of Young People With Diabetes
New Book Explores the Voices of Young People With Diabetes

Presenting what it calls “an intimate portrayal of the lives of 13 extraordinary young people,” Novo Nordisk has published “Young Voices, Life With Diabetes.”

comments 0 comments - Posted Aug 1, 2005

Alan Moses is the associate vice president of medical affairs for Novo Nordisk Inc.
Alan Moses is the associate vice president of medical affairs for Novo Nordisk Inc.

How does Novo Nordisk continue to evolve in the diabetes care industry?

comments 0 comments - Posted Aug 1, 2005

Keeping Well With Diabetes
Keeping Well With Diabetes

Most of the products reviewed in this column over the past few months have come from glucose meter and insulin pump manufacturers and from independent software companies. This month, we will take a look at an offering from one of the major insulin manufacturers: Keeping Well With Diabetes, a Web-based product from Novo Nordisk.

comments 0 comments - Posted Aug 1, 2005

February 2005

How Easy Is This?

On November 22, 2004, the diabetes business unit of Medtronic, Inc., and Novo Nordisk announced an agreement to develop the first prefilled cartridges designed for use with Paradigm external insulin pumps.

comments 0 comments - Posted Feb 1, 2005

Novo Awards Native American Nursing Scholarships
Novo Awards Native American Nursing Scholarships

Novo Nordisk recently began awarding scholarships to Native American nursing students.

comments 1 comment - Posted Feb 1, 2005

August 2004

Call It Predictable

Insulin detemir, the long-acting insulin analog from Novo Nordisk, has a more predictable blood glucose-lowering effect than both long-acting insulin glargine (Lantus) and NPH.

comments 0 comments - Posted Aug 1, 2004

July 2004

Insulin Detemir Beats NPH at Blood Glucose Control

Blood glucose control with detemir, a long-acting insulin analog, is better than NPH insulin.

comments 0 comments - Posted Jul 1, 2004

May 2004

And the Envelope Please

A videotape sponsored by Novo Nordisk and developed in partnership with the American Association of Clinical Endocrinologists won a Chicago/Midwest Emmy Award.

comments 0 comments - Posted May 1, 2004

Insulin Doser Called Easier to Use Than Vial

A Novo Nordisk-sponsored study demonstrated that eight out of 10 elderly people with diabetes who have visual and motor difficulties preferred the Novolin Innolet doser to vials and syringes.

comments 0 comments - Posted May 1, 2004

February 2004

Novo Nordisk Receives ‘Approvable Letter’ From FDA

On October 8, 2003, Novo Nordisk announced that it had received an “Approvable Letter” from the U.S. Food and Drug Administration (FDA) for insulin detemir, its long-acting insulin analog.

comments 0 comments - Posted Feb 1, 2004

January 2004

Easier Injections

If you have diabetes and use an insulin pen, odds are you don’t live in the United States.

comments 0 comments - Posted Jan 1, 2004

April 2003

Word to the Wise

We hear the statistics so often that we take them for granted.

comments 0 comments - Posted Apr 1, 2003

March 2003

Insulin Usage Continues to Evolve

Looking at a list of the many types of insulin available today is impressive, but there's even more to the story. Overall, patterns of insulin use have changed dynamically during the past six years.

comments 0 comments - Posted Mar 1, 2003

January 2003

Are Rapid-Acting Insulin Analogs Created Equal?

German researchers who compared insulin lispro (Humalog) and insulin aspart (NovoLog) report that the two insulins are equally effective in controlling after-meal blood glucose in people with type 1 diabetes.

comments 0 comments - Posted Jan 1, 2003

December 2002

New 70/30 Insulin Mix Available in Disposable Pen

Novo Nordisk has introduced its NovoLog Mix 70/30, which consists of 70 percent insulin aspart with protamine crystals to slow down absorption and 30 percent NovoLog (insulin aspart).

comments 0 comments - Posted Dec 1, 2002

October 2002

Novo Nordisk Suspends Development of Insulin Sensitizer

Novo Nordisk has suspended development of ragaglitazar—a drug that has potential for regulating both blood-glucose and lipid levels—after finding urine bladder tumors in one mouse and several rats tested with the drug during preclinical trials.

comments 0 comments - Posted Oct 1, 2002

Novo Nordisk Suspends Development of Insulin Sensitizer - Tumors Found in Animal Tests

Novo Nordisk has suspended development of ragaglitazar - a drug that has potential for regulating both blood-glucose and lipid levels-after finding urine bladder tumors in one mouse and several rats tested with the drug during preclinical trials.

comments 0 comments - Posted Oct 1, 2002

September 2002

Developing Solutions

With the World Health Organization estimating that 70 percent of all new cases of diabetes are expected to appear in developing nations, Novo Nordisk has committed $60 million over the next decade to the World Diabetes Foundation (WDF). Funding for the WDF also will be sought from other sources.

comments 0 comments - Posted Sep 1, 2002

Developing Solutions: World Diabetes Foundation Receives Big Bucks

With the World Health Organization estimating that 70 percent of all new cases of diabetes are expected to appear in developing nations, Novo Nordisk has committed $60 million over the next decade to the World Diabetes Foundation (WDF). Funding for the WDF also will be sought from other sources.

comments 0 comments - Posted Sep 1, 2002

July 2002

Down to Halves

Novo Nordisk, of Princeton, New Jersey, has received approval from the U.S. Food and Drug Administration for a new insulin delivery system with a special feature and design.

comments 0 comments - Posted Jul 1, 2002

Team Effort

Novo Nordisk Pharmaceuticals of Princeton, New Jersey, has formed an alliance with Rite Aid Corporation to provide better care for people with diabetes who use insulin therapy. Rite Aid stores will give preferred status to insulin formulations and delivery systems produced by Novo Nordisk, according to a press release from the pharmaceutical company.

comments 0 comments - Posted Jul 1, 2002

June 2002

Pick a Bolus!

Normal bolus! Extended bolus! Square-wave bolus! Combination bolus! Dual-wave bolus!

comments 0 comments - Posted Jun 1, 2002

Letters to the Editor

I Developed Type 2 Diabetes From Polycystic Ovary Syndrome

comments 0 comments - Posted Jun 1, 2002

April 2002

Your Best Shot?

Insulin delivery devices come in many shapes and sizes. The most familiar and widely used in the United States is the traditional insulin syringe.

comments 1 comment - Posted Apr 1, 2002

March 2002

Rapid-Acting Insulin Now Approved for Use With Pumps

NovoLog (insulin aspart) has received supplemental approval from the U.S. Food and Drug Administration for use in external insulin pumps, Novo Nordisk Pharmaceuticals announced in December 2001. This decision, according to Novo Nordisk, makes NovoLog the only rapid-acting insulin analog to be indicated for use with pumps.

comments 0 comments - Posted Mar 1, 2002

New Insulin Delivery System Now Available

Novo Nordisk Pharmaceuticals of Denmark is now offering its InnoLet insulin delivery system for insulin users. The easy-to-use device is specifically designed for people with diabetes who have poor eyesight, weak manual dexterity or difficulty following the steps normally required to self-inject insulin.

comments 0 comments - Posted Mar 1, 2002

"Kiss NPH Goodbye"

The evolution of insulin has taken a turn that even Banting and Best could not have foreseen when they discovered the hormone back in the 1920s.

comments 0 comments - Posted Mar 1, 2002

February 2002

Study Shows Insulin Therapy Lowers Mortality Rates in Critically Ill Hospital Patients

Giving intensive insulin therapy to patients with elevated blood-glucose levels in the surgical intensive care unit (ICU) of a hospital significantly reduces their chance of death, even if the patients did not previously have diabetes, say researchers in Belgium. Greet Van den Berghe, MD, PhD, and colleagues reported their results in the November 8, 2001, issue of The New England Journal of Medicine.

comments 0 comments - Posted Feb 1, 2002

My Personal Experience Using the New NovoLog Insulin

As you may be aware, NovoLog (insulin aspart) is the new rapid-acting insulin analog from Novo Nordisk Pharmaceuticals, Inc. On paper, its action is supposed to be similar to Lilly's Humalog (insulin lispro). However, my experience, as well as the experiences of other people I've talked to who are using it in pumps, is very different.

comments 0 comments - Posted Feb 1, 2002

January 2002

Novo Teams Up for Worldly Cause

On November 13, 2001, Novo Nordisk announced a decision to establish an international foundation called the World Diabetes Foundation (WDF) with the purpose of supporting projects that will improve diabetes care in developing countries.

comments 0 comments - Posted Jan 1, 2002

Thanks But No Thanks

On October 29, 2001, Novo Nordisk announced it will continue the development of its dual-acting insulin sensitizer without the involvement of Novartis Pharma. The insulin sensitizer, called NN622, is currently in development for the treatment of type 2 diabetes.

comments 0 comments - Posted Jan 1, 2002

November 2001

The Need for Speed

On September 18, Novo Nordisk Pharmaceuticals announced that its rapid-acting insulin aspart (NovoLog) is now available in the United States.

comments 0 comments - Posted Nov 1, 2001

Glucagon Injections Not Done Right

The majority of parents do not correctly administer Glucagon, according to the results of a recent study.

comments 0 comments - Posted Nov 1, 2001

September 2001

Do You, Insulin Pen, Take This BG Meter?

"I think the InDuo is the cat's meow," says Jane Seley, RN, NP, CDE, a doctoral candidate at New York University. "It's fast, easy and accurate."

comments 0 comments - Posted Sep 1, 2001

Gasp!

Exubera, an inhalable insulin being developed by Inhale Theraputics of San Carlos, California, and Pfizer, might have to wait a little while longer until it ‘breathes' life into the diabetes market.

comments 0 comments - Posted Sep 1, 2001

August 2001

15,000 Miles and Counting: Type 1 Bicyclist Sees the World

For Marco Meijerink, having type 1 diabetes is a challenge, but it is not his biggest challenge.

comments 0 comments - Posted Aug 1, 2001

Rapid-Acting Insulin Good for Controlling Nighttime Hypoglycemia

Taking rapid-acting insulin before meals may reduce major incidents of nighttime hypoglycemia and minor incidents of daytime hypoglycemia, according to research conducted by Novo Nordisk presented at the ADA's scientific sessions in June.

comments 0 comments - Posted Aug 1, 2001

July 2001

One-Shot-A-Day Insulin is Here

In July 1999, John Buse, MD, PhD, CDE, director of the University of North Carolina's Diabetes Center told Diabetes Health that patients enrolled in clinical trials for insulin glargine (Lantus) absolutely "loved" the 24-hour-a-day long-acting (basal) insulin. Most of the people who participated in the clinical trials were not doing well on just NPH or Ultralente, and Lantus improved their control. However, Buse added, "[The clinical-trial participants are] upset that they cannot continue on it." That was because, at the time, the clinical trials had ended and the participants were told they would have to wait at least one year for FDA approval of Lantus and longer until they could get their hands on it.

comments 0 comments - Posted Jul 1, 2001

NPH Varies 20 to 30 Percent Daily

A new basal insulin now in Phase III trials worldwide promises to offer a smoother action than NPH with a more predictable activity curve.

comments 0 comments - Posted Jul 1, 2001

Drug Company Reprimanded for False Advertising

Novo Nordisk Pharmaceuticals of Denmark violated federal regulations for inaccurately representing the type 2 drug Prandin (repaglinide) in promotional materials, according to the U.S. Food and Drug Administration (FDA).

comments 0 comments - Posted Jul 1, 2001

May 2001

Injecting Made Easy

On March 19, Novo Nordisk Pharmaceuticals announced that the U.S. Food and Drug Administration has approved its Innovo "dial-a-dose" insulin-delivery device. The device is expected to be available for people with diabetes later this year.

comments 0 comments - Posted May 1, 2001

April 2001

Control In Motion—Get On Board the “Diabetes Bus”

For Kim Hanchette, MEd, CDE, keeping up with the diabetes Joneses has never been a problem. With the conclusion of the Diabetes Control and Complications Trial in 1993, Hanchette says most doctors in her hometown of Raleigh, North Carolina, had come to embrace the concept of self-management. As a CDE at an outpatient clinic there, Hanchette had her work cut out for her, with patients flowing in at a steady stream for classes on nutrition, glucose levels, exercise and medication.

comments 0 comments - Posted Apr 1, 2001

February 2001

Mail-Order Insulins Can Go Bad

Many people with diabetes suspect that the insulin they get by mail sometimes has lost its effectiveness. Now, a study has proven their suspicions are probably true, causing the medical community to question mail-order pharmacies and bring people back to their community pharmacies, where face-to-face treatment delivers to them the best care possible.

comments 0 comments - Posted Feb 1, 2001

Keeping an Eye On Your Insulin

For millions of people with diabetes, technology has supplied us with wonderful, helpful aids to help control blood sugar. While some of these medications come in pill form and remain stable when stored out of light and at moderate temperatures, people with diabetes who use insulin need to depend on more than technology to make sure their insulin is in top form.

comments 1 comment - Posted Feb 1, 2001

January 2001

Diabetes Conference in Mexico City Looks to the Future

In November 2000, three new products for people with diabetes were demonstrated at the 17th Congress of the International Diabetes Federation in Mexico City.

comments 0 comments - Posted Jan 1, 2001

December 2000

Limiting Body's Response to Glucagon Holds Promise for Type 2s

Normally a stranger to such parts, diabetes was at the top of the marquee at this year's American Chemical Society, held in Washington, D.C. Three studies conducted by pharmaceutical companies revealed potential for glucagon-receptor-blocking compounds as a means of controlling type 2 diabetes.

comments 0 comments - Posted Dec 1, 2000

Low Cost Insulin Available through Major Retailer

On August 31, Wal-Mart announced that people with diabetes will have a new, low-cost option for insulin.

comments 11 comments - Posted Dec 1, 2000

August 2000

Novo's Rapid-acting Insulin Given FDA Approval

On June 8, Novo Nordisk announced the Food and Drug Administration approved insulin aspart (NovoLog), its new rapid-acting insulin analogue.

comments 0 comments - Posted Aug 1, 2000

July 2000

Both Sides Now

You'll find this months "letters to the editor" to be very interesting. On several topics, our readers are clearly divided. Our article on nighttime hypoglycemia shocked one reader and drew praise from another.

comments 0 comments - Posted Jul 1, 2000

What They're Talking About Around the Water Cooler

10,000 Babies Per Year to be Screened for Diabetes Risk Genes in Sweden

comments 0 comments - Posted Jul 1, 2000

June 2000

New Long-Acting Insulin Shown to be Better

There was an outcry from insulin users when Novo Nordisk and Eli Lilly decided to withdraw animal-derived basal insulins from the market and replace them with biosynthetic NPH and Ultralente, which many consumers consider inferior. These same critics are hoping that a new generation of basal insulins such as HOE901, Basulin and Lantus will prove to be more effective.

comments 0 comments - Posted Jun 1, 2000

Novo to Sue Aventis Over Long-acting Insulin — Claims Patent Infringement

On April 27, three days after glargine (Lantus) was approved by the U.S. Food and Drug Administration, Novo Nordisk filed a lawsuit with the Court of Dusseldorf in Germany against Aventis for patent infringement.

comments 0 comments - Posted Jun 1, 2000

May 2000

Questions and Answers

Q: Are there any studies of dietary changes to help with problems of gastroparesis? My daughter has had type 1 diabetes for 32 years and is now suffering complications, gastroparesis being one of particular concern.

comments 0 comments - Posted May 1, 2000

April 2000

Questions and Answers

I thought Daniel Trecroci's foot care feature in the February issue ("Does the Shoe Fit? Important New Products for the Diabetic Foot") was very well written and organized. It is always good to express opinions from a variety of specialties.

comments 0 comments - Posted Apr 1, 2000

Insulin Outside America

Dr. Sharad Pendsey is a physician based in Nagpur, India. Pendsey recalls the story of a girl named Sudha who came to him when she was eight-years old. Sudha had just been diagnosed with type 1 diabetes. When she was discharged from the hospital, Pendsey explained to Sudha's impoverished parents that she would have to take insulin to stay alive. Pendsey recalls Sudha's parents asking, "Doctor, if I understand you correctly, Sudha has to take insulin every day for the rest of her life?" Pendsey nodded yes, and said that Sudha would die if she didn't. The parents understood the predicament, but could not afford the cost of her insulin. One month later, Pendsey learned that Sudha had died.

comments 0 comments - Posted Apr 1, 2000

Letters to the Editor

I thought Daniel Trecroci's foot care feature in the February issue ("Does the Shoe Fit? Important New Products for the Diabetic Foot") was very well written and organized. It is always good to express opinions from a variety of specialties.

comments 0 comments - Posted Apr 1, 2000

What They’re Talking About Around the Water Cooler

FDA Official Wants Rezulin Pulled

comments 0 comments - Posted Apr 1, 2000

February 2000

Lispro For Pumpers With Hypoglycemia Unawareness

Researchers at the Walton Diabetes Center in Liverpool, United Kingdom, are saying that in certain individuals with poor hypoglycemia unawareness, the use of lispro in insulin pumps may increase the frequency of hypoglycemia.

comments 0 comments - Posted Feb 1, 2000

Letters to the Editor

The Freedom to Operate a Vehicle

comments 0 comments - Posted Feb 1, 2000

Novo to Help Develop Long-Acting Basal Insulin

Flamel Technologies and Novo Nordisk announced that they will collaborate on developing Basulin, a long-acting, once-a-day formulation of human insulin that can be used by people with type 1 and 2 diabetes.

comments 0 comments - Posted Feb 1, 2000

December 1999

Lilly Draws Wrath Over Discontinued Insulin

A high school Spanish teacher in California, Linda Vernier relies on beef-pork insulin from Eli Lilly and Co. to stay healthy.

comments 0 comments - Posted Dec 1, 1999

Lilly and Novo Nordisk Go to Battle Over Rapid-Acting Insulin Patent

Insulin aspart, Novo Nordisk's rapid-acting insulin, has been cleared for sale in Europe under the brand name Novo Rapid. Its arrival on the United States market still depends on the outcome of court battles between Novo Nordisk and its insulin-manufacturing competitor, Eli Lilly.

comments 0 comments - Posted Dec 1, 1999

September 1999

Letters to the Editor

Doctors Say "Noncompliant" is an Irrelevant Term

comments 1 comment - Posted Sep 1, 1999

August 1999

Questions and Answers

Q: I have been taking vitamin E for over 10 years. I started on 100 mg., then moved up to 200 mg. About six months ago, I switched to 400 mg. Recently, however, I started having swelling in my lower legs and feet. I also started having blisters that oozed on my legs.

comments 0 comments - Posted Aug 1, 1999

British Insulin Maker Fights To Bring Animal Insulin to the United States

Beef-pork insulin will soon disappear in the United States, leaving thousands of people with diabetes without the insulin they feel is essential to their lives. Ever since insulin manufacturers Eli Lilly and Novo Nordisk announced that they would no longer sell beef-pork insulin, American activists have been fighting to import it from the United Kingdom and Brazil, where it is still made and widely available. The activists work on behalf of those who say that human insulin causes side effects in them, the most frequently reported being that they no longer get any physical warning when their blood sugars drop.

comments 1 comment - Posted Aug 1, 1999

July 1999

Letters to the Editor

Visually Impaired Need Braille on Insulin Vials

comments 0 comments - Posted Jul 1, 1999

June 1999

British Diabetic Association Accused of Hiding Information About Human Insulin Reactions

The British Diabetic Association (BDA) has been accused in major British newspapers of failing in its mission of advocating for people with diabetes, by hiding information about human insulin's harmful effects on some people.

comments 0 comments - Posted Jun 1, 1999

Resources to Get the Insulin You Need

Remember, 100 percent pork insulin is still available from Novo Nordisk and Eli Lilly. Ask for it at your pharmacy. Importing the insulin you need is also possible. Learn about importation from the two American groups listed below.

comments 0 comments - Posted Jun 1, 1999

April 1999

Catching Up with Miss America—Nicole Johnson's Crusade for Diabetes Awareness

Nicole Johnson: Congratulations. I saw Scott King's letter in Ann Landers. How wonderful that it was published.

comments 0 comments - Posted Apr 1, 1999

Letters to the Editor

Readers Desperate to Hang On to Animal Insulin

comments 0 comments - Posted Apr 1, 1999

January 1999

Lily, Novo Exchange Fire Over Rapid-Acting Insulin

Eli Lilly and Novo Nordisk are brawling in courts worldwide over Novo's steps to introduce its rapid-acting insulin.

comments 0 comments - Posted Jan 1, 1999

December 1998

Companies Try to Leave Each Other in Inhalable Insulin Dust

Two more contenders have stepped into the ring in the fight for inhalable insulin. Eli Lilly and Company and Dura Pharmaceuticals, a supplier for respiratory conditions, are financially uniting efforts to achieve inhalable insulin. Using an undisclosed sum from Lilly, Dura will try to suit its technology for a dry powder inhaler (DPI) for use with insulin.

comments 0 comments - Posted Dec 1, 1998

November 1998

20-Year Landmark Study Completed in the UK

In early September, researchers concluded a landmark, 20-year study on type 2 diabetes. The $38.6 million study, known as the United Kingdom Prospective Diabetes Study (UKPDS), examined the effects of various therapies on patients with type 2 diabetes. The study is considered the first of its kind in relation to examining diet, oral drug and insulin therapies for patients with type 2 diabetes.

comments 0 comments - Posted Nov 1, 1998

Beef Insulin Pulled in Canada

For many years, sulfated beef insulin has been produced for insulin users. By 1993 there were 26 people taking sulfated beef insulin in Canada. By 1996 only 15 people were still using sulfated beef insulin.

comments 0 comments - Posted Nov 1, 1998

Diabetes Educators Raise $5,000 in Walk/Jog-a-Thon

During the American Association of Diabetes Educators (AADE) annual meeting in Minneapolis this August, Novo Nordisk Pharmaceuticals held its 17th annual "Walk/Jog-A-Thon" for diabetes awareness. At the early hour of 6 a.m. on a Saturday morning, more than 800 diabetes educators raced for the company's pledge of $5,000 to the AADE Foundation.

comments 0 comments - Posted Nov 1, 1998

October 1998

Do You Buy It?

Diabetes is a rich and growing industry. Last year alone, the diabetes medication market grew 23 percent. Furthermore, 2,186 more of us are diagnosed with diabetes in this country every day. Do the math and you'll see a growing market.

comments 0 comments - Posted Oct 1, 1998

Parting Causes Great Sorrow - Beef-Pork Insulin Users Prepare to Switch

Christine Klemp of West Bend, Wisconsin, received a shock when she opened her box of insulin on August 16. A message printed in red ink said, "This insulin will be discontinued. Contact your physician to change to another insulin." Klemp was horrified, because this particular insulin (Iletin I beef-pork) is the only insulin that works well for her. "My life is about to come to an end. I just could not believe this was happening."

comments 0 comments - Posted Oct 1, 1998

August 1998

Waiting to Exhale... But Don't Hold Your Breath

Before eating lunch at a restaurant, Jim loads his foil packs of insulin into a device about the size of a large flashlight. He then presses a button which releases a cloud of insulin into the clear chamber of the device. He takes a slow, deep draw of powdered insulin into his lungs.

comments 0 comments - Posted Aug 1, 1998

Prandin Helps Smooth Glucose Swings

A series of new studies has shown that Prandin (repaglinide), a new oral antidiabetic drug, is effective in providing 24-hour control of blood glucose levels in people with type 2 diabetes. Prandin stimulates beta cells within the pancreas to produce insulin and is taken just before each meal, when insulin is needed. The drug reduces risk of hyperinsulinemia (excess insulin) or severe hypoglycemia (low glucose levels) by allowing insulin levels to return toward baseline between meals and at night.

comments 0 comments - Posted Aug 1, 1998

July 1998

Novo Introduces New Type 2 Medication

Novo Nordisk Pharmaceuticals has introduced a new oral antidiabetic agent called Prandin (repaglinide). The medication is intended for people with type 2 diabetes, who are unable to satisfactorily control their hyperglycemia through diet and exercise. It can also be used in combination with metformin, which works with Prandin to control blood sugars.

comments 0 comments - Posted Jul 1, 1998

May 1998

Novo Nordisk Loses Pen Battle

In March a U.S. District Court issued a preliminary injunction in favor of Becton Dickinson, a major manufacturer of insulin pens and needles, in its false and misleading advertising suit against its Danish competitor, Novo Nordisk. The court prohibited Novo Nordisk from claiming that its NovoPen 1.5 and Novolin Pre-filled devices can only be used with NovoFine needles.

comments 0 comments - Posted May 1, 1998

February 1998

New Way to Stimulate Your Pancreas

Prandin (repaglinide), a new type 2 oral medication manufactured by Novo Nordisk, has been approved by the FDA.

comments 0 comments - Posted Feb 1, 1998

Insulin Bottles More Accessible for the Visually Impaired

Eli Lilly, Novo Nordisk and the FDA met in June of last year to discuss how to make insulin bottles more distinguishable for the visually impaired. Participants agreed that a coding system using horizontal raised bars would be the most effective. If the FDA accepts the plan, the four code categories will be as follows: one bar for rapid-acting insulin analogs, two bars for regular insulins, three bars for insulin mixtures and four bars for intermediate- and long-acting insulins.

comments 0 comments - Posted Feb 1, 1998

January 1998

Letters to the Editor

Psychological Support for Dieters

comments 0 comments - Posted Jan 1, 1998

December 1997

Questions and Answers

Beating the Bruise Blues

comments 0 comments - Posted Dec 1, 1997

November 1997

Novo Protects Its Own - Sues Four Companies

Novo Nordisk has recently filed a patent infringement lawsuit in New Jersey Federal Court against Genentech, Eli Lilly, Pharmacia & Upjohn and Serono corporations. The companies all make and/or sell biosynthetic human growth hormone products that compete with Novo's Norditropin.

comments 0 comments - Posted Nov 1, 1997

October 1997

I Want My Iletin I!

When human insulin first appeared on the market it was thought to be a "special" insulin and the beef/pork insulin that I had taken for years was termed "standard" insulin. A lot has changed since those days. What was once thought to be the standard is now in danger of being pulled from the market.

comments 0 comments - Posted Oct 1, 1997

British Diabetes Association Statement on Human and Animal Insulins, 1997

The British Diabetic Association's (BDA's) insulin campaign is committed to securing choice for people with diabetes for the kind of insulin that they use. The BDA is therefore committed to securing long-term availability of animal and human insulins, and provision of animal insulins in pen cartridges.

comments 0 comments - Posted Oct 1, 1997

Canadian Diabetes Association Recommendations for Human and Animal Insulins, 1997

(Our) survey results indicate that for some people, changing insulins has a negative impact on their health, well-being and quality of life. People need more information as to the reasons for changing their insulin and they need to have the choice. They need the support of their physicians and their diabetes health care teams during this time of change-over. The (Canadian) National Advocacy Committee is committed to advocating for the continuation of beef/pork insulins for those whose health, well-being or quality of life will be affected by the change.

comments 0 comments - Posted Oct 1, 1997

May 1997

The ABCs of Insulin Care

Differing opinions about how to best care for insulin are stirring up a whirlwind of confusion. Over the last few months readers have been sending their questions and concerns to DIABETES HEALTH. The questions are simple enough: What is the best temperature to keep my insulin? Is it okay to use insulin past the expiration date? How should I mix my insulin? But answers to these questions can vary, making it hard to be sure one is doing the right thing. Here the questions and comments of insulin users will be presented with the recommendations of the companies who produce insulin.

comments 0 comments - Posted May 1, 1997

Letters to the Editor

Marching for a Cure

comments 0 comments - Posted May 1, 1997

February 1997

Injection Aids: Readers Sound Off

The following is an informal, unscientific review of some of the leading injection aid products on the market. It is not the result of a comprehensive consumer satisfaction survey. While we are thankful for the responses from our readers included in the article, it should be noted that they are the opinions solely of the individuals and do not reflect the views of Diabetes Health.

comments 0 comments - Posted Feb 1, 1997

Grab Bag

Some criminals will go to enormous lengths to beat a rap. The Palm Beach Post reported a Florida man, Wesley Shaffer, attempted to convince a jury that he was an undiagnosed diabetic who had been driven insane by eating large amounts of cotton candy. The jury didn't buy it. Mr. Shaffer was convicted on burglary charges, and then promptly escorted to jail-far from the tempting dangers of cotton candy.

comments 0 comments - Posted Feb 1, 1997

January 1997

Long-Acting Insulins - Shake 'em Up Baby

Are you in danger of hypoglycemia without even knowing it? A recent study of people with insulin dependent diabetes revealed that most NPH-insulin users shake or roll their insulin only four times before injection, 16 times fewer than is necessary. This can result in concentrations of NPH that could be either too low or too high and can cause day to day blood sugar fluctuations.

comments 0 comments - Posted Jan 1, 1997

Complementary Therapy: Reader's Respond

Knowledge Leads to Advancements

comments 0 comments - Posted Jan 1, 1997

October 1996

Novo Sues Lilly Over Insulin Cartridges

Pharmaceutical giant Novo Nordisk filed suit against major competitor Eli Lilly on Aug. 1, alleging that Lilly deliberately created false and misleading packaging information for its new Humulin cartridges.

comments 0 comments - Posted Oct 1, 1996

Grab Bag

In India, a country with 25 million people with diabetes, Novo Nordisk human insulin is six times more expensive than locally produced insulin, according to a June, 19, 1996 Chemical Business Newsbase report, making the Novo product a choice for the affluent only.

comments 0 comments - Posted Oct 1, 1996

September 1996

The Days of Animal Insulin May be Numbered — Should Corporations Make the Decision?

The future of animal insulin looks grim. Now that 90 percent of people with type I diabetes are taking human insulin, no one denies that the era of animal insulin may be coming to a close. But for those who have come to depend on it, the availability of animal insulin is vital.

comments 0 comments - Posted Sep 1, 1996

Advocates Struggle to Keep Animal Insulin

How do you get a giant pharmaceutical company to listen? Make a lot of noise, say the founders of three patient advocate groups that formed when animal insulins were pulled from the market in Europe and North America.

comments 0 comments - Posted Sep 1, 1996

April 1996

Letters to the Editor

Animal Insulin Becoming Extinct?

comments 0 comments - Posted Apr 1, 1996

October 1995

Giants Join Forces

Novo Nordisk, the world's largest insulin producer, and LifeScan, Inc., the leading maker of blood glucose monitoring systems, have announced a worldwide alliance to enhance diabetes management solutions.

comments 0 comments - Posted Oct 1, 1995

78% Of Diabetics Want It - The Latest From Novo Nordisk

Novo Nordisk recently introduced Novolin Prefilled, a self-contained insulin delivery system, in two additional human insulin forms-Regular (short acting) and NPH (intermediate acting).

comments 0 comments - Posted Oct 1, 1995

September 1995

Some Exciting Patents

In a reaction to research that shows a relationship between infant consumption of cow's milk and the development of diabetes, Nutrition Concepts Inc. proposes a method of making milk "safe."

comments 0 comments - Posted Sep 1, 1995

April 1995

More Readers Respond to Insulin Articles

Eli Lilly responded to Ressmeyer with a letter informing him that "The rising costs of continued production of some formulations, in view of decreasing therapeutic use of them here and abroad, forced us to reevaluate our strategy. The result was that we substantially narrowed our insulin product line by discontinuing some lesser used products, such as animal Ultralente insulin."

comments 0 comments - Posted Apr 1, 1995

Patent Watch

Non-Invasive Blood Glucose Reading

comments 0 comments - Posted Apr 1, 1995

March 1995

Readers Respond to Insulin Articles

In our November and December issues we tackled the topic of animal insulins being pulled off the market by Novo Nordisk in our article "Where's the Beef?" Also in my column I wrote about my personal experiences with taking beef Ultralente insulin (beef U). I had discovered an insulin which worked perfectly for me while I was off my insulin pump. While taking beef U I had better blood sugar control than I had ever been able to achieve before. The rub in this matter is that the insulin, beef U is no longer available.

comments 0 comments - Posted Mar 1, 1995

End to Velosulin Human Insulin Shortage Announced by Novo Nordisk

Novo Nordisk has announced an end to the shortage of Velosulin Human insulin, which was in limited supply at the end of 1994.

comments 0 comments - Posted Mar 1, 1995

February 1995

No Mountain Too High for Bill Bicksler—Type 1 Diabetes

They say there are two types of people in this world; Those who go around obstacles and those who just go right over them.

comments 0 comments - Posted Feb 1, 1995

December 1994

The British Insulin Debate

Introduction This article was originally published in Balance, the magazine of the British Diabetes Association (BDA), and was written for a British audience.

comments 0 comments - Posted Dec 1, 1994

April 1994

What Was The DCCT All About

Dr. Alan Marcus is a diabetes specialist who practices in Laguna Hills, California. He is a medical advisor to MiniMed Technologies, a spokesperson for Novo Nordisk, and an Assistant Clinical Professor of Medicine at the USC School of Medicine.

comments 0 comments - Posted Apr 1, 1994

December 1992

Captain Novolin

The long-awaited video game, Captain Novolin, is now available to the public, and in time for the holidays. Test markets have shown Captain Novolin to be a hit with children who have diabetes, and their friends and family enjoy it also.

comments 0 comments - Posted Dec 1, 1992

November 1992

Dr. Marcus’ Diabetes Tip

Dr. Alan Marcus is a diabetes specialist who practices in Laguna Hills, California. He is also a medical advisor to MiniMed Technologies and a spokesperson for Novo Nordisk Insulin. Dr. Marcus also serves as Assistant Clinical Professor of Medicine for the USC School of Medicine.

comments 0 comments - Posted Nov 1, 1992

©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.